Nytenso5 mg

Nytenso is an atypical antidepressant approved for the following use:

Established/FDA-Approved Use

• Major Depressive Disorder (MDD) in adults — Nytenso is indicated for the acute and maintenance treatment of major depressive disorder in adult patients. Efficacy has been demonstrated in multiple randomized, placebo-controlled clinical trials.

Not an Approved Use

Nytenso has been studied in children and adolescents with MDD, but clinical trials did not demonstrate efficacy in this population, and it is not approved for use in patients under 18 years of age (see Pediatric Uses).

Nytenso is not approved for anxiety disorders, bipolar depression, or other psychiatric conditions; any such use would be off-label and should only be undertaken under close physician supervision.

Each film-coated tablet contains Vortioxetine Hydrobromide equivalent to vortioxetine base. Vortioxetine Hydrobromide is typically available in strengths of 5 mg, 10 mg, 15 mg, and 20 mg (expressed as vortioxetine base) for oral administration.

Tablets also contain standard pharmaceutical excipients (fillers, binders, and film-coating agents) that do not affect the therapeutic action of the active ingredient.

Nytenso is an oral, atypical antidepressant belonging to a class sometimes called a "serotonin modulator and stimulator" (SMS). Unlike selective serotonin reuptake inhibitors (SSRIs), Nytenso combines serotonin transporter (SERT) inhibition with direct activity at several serotonin receptor subtypes, giving it a distinct, multimodal pharmacological profile.

Nytenso is used for the treatment of major depressive disorder in adults and is taken once daily by mouth, with or without food.

Nytenso belongs to the therapeutic class of atypical antidepressants, specifically classified as a serotonin modulator and stimulator (SMS) with a multimodal mechanism of action. It is distinct from classic SSRIs and SNRIs.

Mechanism of Action

Vortioxetine Hydrobromide is believed to exert its antidepressant effect through a multimodal mechanism: inhibition of the serotonin transporter (SERT), combined with direct modulation of several serotonin (5-HT) receptor subtypes. Specifically, Vortioxetine Hydrobromide acts as an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors, in addition to inhibiting serotonin reuptake.

Pharmacokinetics

• Absorption: Well absorbed orally; food does not significantly affect absorption.
• Metabolism: Extensively metabolized in the liver, primarily via CYP2D6, with minor contributions from CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8, and CYP2B6.
• Half-life: Approximately 66 hours, supporting once-daily dosing and allowing several weeks to reach steady state.
• Elimination: Excreted mainly as inactive metabolites in urine and feces.

Nytenso tablets are taken by mouth once daily, with or without food, at approximately the same time each day to maintain consistent blood levels. Tablets should be swallowed whole with water; they may be crushed and mixed into soft food if swallowing whole tablets is difficult. Do not stop Nytenso abruptly without consulting a physician, as gradual dose tapering is generally recommended.

Nytenso has several clinically significant drug interactions. Its use with monoamine oxidase inhibitors (MAOIs) is contraindicated (see Contraindications) due to the risk of serotonin syndrome.

Serotonergic Drugs

Concomitant use of Nytenso with other serotonergic agents — including triptans, other antidepressants (SSRIs, SNRIs, tricyclics), tramadol, lithium, St. John's Wort, or fentanyl — increases the risk of serotonin syndrome (agitation, hallucination, tachycardia, hyperthermia, tremor, rigidity, incoordination). Combination requires caution and close monitoring; discontinue immediately if serotonin syndrome is suspected.

Bleeding Risk

Concomitant use with NSAIDs, aspirin, warfarin, or other anticoagulants may increase the risk of bleeding due to the effect of serotonergic drugs on platelet function. Monitor for signs of bleeding.

CYP2D6 Inhibitors and Inducers

Strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine) increase Nytenso plasma concentrations and generally require a dose reduction. Strong CYP inducers (e.g., rifampin, carbamazepine, phenytoin) reduce Nytenso concentrations and may require a dose increase.

Alcohol

Nytenso does not appear to potentiate the cognitive/motor effects of alcohol in studies, but concurrent use is generally discouraged in patients with depression.

The most common side effects of Nytenso, generally dose-related, include:

• Nausea — the most frequently reported side effect, usually mild to moderate and often diminishing over the first 1–2 weeks.
• Constipation
• Vomiting
• Sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia) — reported less frequently than with SSRIs
• Dizziness
• Dry mouth
• Diarrhea
• Pruritus

Less Common but Serious Effects

Serotonin syndrome, abnormal bleeding, activation of mania/hypomania, angle-closure glaucoma, and hyponatremia can occur — see Precautions and Warnings and Drug Interactions for full detail. Suicidal thoughts and behaviors are addressed under the boxed warning in Precautions and Warnings.

Pregnancy

Data on the use of Nytenso in pregnant women are limited. Nytenso should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close medical supervision. Neonates exposed to serotonergic antidepressants late in the third trimester have, in rare cases, developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. A physician must be consulted before starting, stopping, or continuing Nytenso during pregnancy.

Lactation

Nytenso and its metabolites are present in human breast milk. Because of the potential for adverse effects in a breastfed infant, a decision should be made whether to discontinue breastfeeding or discontinue Nytenso, taking into account the importance of treatment to the mother. This should be done only in consultation with a physician.

Boxed Warning: Suicidal Thoughts and Behaviors

Nytenso and other antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25 years of age) in short-term clinical trials. Nytenso is not approved for use in pediatric patients (see Pediatric Uses). All patients started on Nytenso should be monitored closely for clinical worsening and emergence of suicidal thoughts or behavior, especially during the first few months of treatment and following dose changes. Families and caregivers should be advised of the need for close observation.

Serotonin Syndrome

Serotonin syndrome can occur with Nytenso, particularly with concomitant serotonergic drugs (see Interactions). Discontinue Nytenso immediately if this is suspected and seek emergency medical care.

Abnormal Bleeding

Nytenso may increase the risk of bleeding, particularly with concomitant NSAIDs, aspirin, or anticoagulants (see Interactions).

Activation of Mania/Hypomania

Nytenso should be used with caution in patients with a history of bipolar disorder, as antidepressants can precipitate a manic or hypomanic episode. Screen for bipolar disorder before initiating treatment.

Angle-Closure Glaucoma

Pupillary dilation associated with Nytenso use can trigger an angle-closure attack in patients with anatomically narrow angles.

Hyponatremia

Hyponatremia, sometimes due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), has been reported with serotonergic antidepressants, particularly in elderly patients and those on diuretics.

Discontinuation Symptoms

Abrupt discontinuation of Nytenso may cause discontinuation symptoms; a gradual dose reduction is generally recommended rather than abrupt cessation.

Hepatic/Renal Impairment

Use with caution in patients with significant hepatic or renal impairment (see Dosage and Administration).

Reported symptoms of Nytenso overdose include nausea, postural dizziness, generalized pruritus, somnolence, and flushing; overdoses have generally been reported as tolerated without severe complications when Nytenso was taken alone, but risk increases substantially when combined with other central nervous system depressants or serotonergic drugs.

There is no specific antidote for Nytenso overdose. Anyone suspected of having taken an overdose of Nytenso should seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and should be managed in a medical facility, including monitoring for signs of serotonin syndrome and cardiac status as needed.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Patients over 65 years may have an increased risk of hyponatremia and are generally recommended not to exceed 10 mg once daily of Nytenso due to limited safety data at higher doses.

Hepatic Impairment

No dose adjustment is needed for mild to moderate hepatic impairment; Nytenso has not been well studied in severe hepatic impairment and should be used with caution.

Renal Impairment

No dose adjustment of Nytenso is required based on renal function.

CYP2D6 Poor Metabolizers

Patients who are known CYP2D6 poor metabolizers may have higher Nytenso exposure; a lower maximum dose should be considered.

Pediatric Patients

See Pediatric Uses.

An adequate trial of Nytenso for major depressive disorder is generally considered to be at least 6–8 weeks at an appropriate dose before concluding a lack of response. Once a response is achieved, maintenance treatment is often continued for 6 to 12 months or longer to reduce the risk of relapse, based on individual history and physician judgment. Any decision to stop Nytenso should be made in consultation with a physician, with dose tapered gradually rather than stopped abruptly (see Precautions and Warnings).

Antidepressants; Atypical Antidepressants; Serotonin Modulator and Stimulator (SMS) — the class to which Vortioxetine Hydrobromide belongs.

Vortioxetine Hydrobromide works through a multimodal mechanism of action, combining inhibition of the serotonin transporter (SERT) — which increases synaptic serotonin availability, similar to SSRIs — with direct agonist, partial agonist, and antagonist activity at multiple serotonin (5-HT) receptor subtypes (5-HT1A agonist, 5-HT1B partial agonist, 5-HT3/5-HT1D/5-HT7 antagonist). This combined activity is thought to modulate the release of serotonin as well as other neurotransmitters (norepinephrine, dopamine, acetylcholine, histamine, and glutamate) implicated in mood regulation, distinguishing Vortioxetine Hydrobromide from single-mechanism antidepressants.

C

The safety and efficacy of Nytenso have not been established in pediatric patients. Clinical trials of Nytenso in children and adolescents with major depressive disorder did not demonstrate efficacy, and Nytenso is therefore not approved for use in patients under 18 years of age.

As with other antidepressants, the boxed warning regarding increased risk of suicidal thinking and behavior applies specifically to children, adolescents, and young adults under 25 years of age (see Precautions and Warnings); this warning is a safety concern rather than an indication for pediatric use, and Nytenso should not be prescribed to pediatric patients outside of specialist supervision, if at all.